UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Increases Position in HealthEquity, Inc. $HQY

Key Points

• UBS Asset Management increased its stake in HealthEquity by 1.6%, owning approximately 372,745 shares valued at approximately $32.94 million as of the latest reporting period.
• Analysts are optimistic about HealthEquity, with target prices being raised by multiple firms: Deutsche Bank raised theirs from $98.00 to $115.00 and JMP Securities from $110.00 to $117.00, reflecting a consensus rating of "Buy" with a target price of $119.77.
• HealthEquity's market performance shows a trading price of $93.02, with a 52-week high of $116.65 and a market capitalization of $8.01 billion.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 1.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 372,745 shares of the company's stock after acquiring an additional 5,992 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.43% of HealthEquity worth $32,939,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC raised its stake in shares of HealthEquity by 24.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 6,380 shares of the company's stock worth $564,000 after purchasing an additional 1,265 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in HealthEquity by 7,983.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,655 shares of the company's stock valued at $2,179,000 after acquiring an additional 24,350 shares during the last quarter. GAMMA Investing LLC increased its position in shares of HealthEquity by 25.9% during the first quarter. GAMMA Investing LLC now owns 1,571 shares of the company's stock worth $139,000 after acquiring an additional 323 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in HealthEquity by 995.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 639,345 shares of the company's stock valued at $56,500,000 after acquiring an additional 580,988 shares during the period. Finally, WCM Investment Management LLC bought a new position in shares of HealthEquity in the first quarter valued at $20,230,000. Institutional investors own 99.55% of the company's stock.

Insider Activity at HealthEquity

In other news, EVP Michael Henry Fiore sold 1,794 shares of the business's stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $101.73, for a total value of $182,503.62. Following the sale, the executive vice president directly owned 53,225 shares in the company, valued at $5,414,579.25. The trade was a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.50% of the company's stock.

Analyst Ratings Changes

HQY has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft increased their price target on shares of HealthEquity from $98.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, June 5th. Royal Bank Of Canada boosted their price target on shares of HealthEquity from $109.00 to $110.00 and gave the company an "outperform" rating in a research report on Wednesday, September 3rd. Raymond James Financial restated a "strong-buy" rating and issued a $120.00 price objective (up from $115.00) on shares of HealthEquity in a report on Tuesday, July 8th. JMP Securities increased their price objective on shares of HealthEquity from $110.00 to $117.00 and gave the stock a "market outperform" rating in a research note on Wednesday, June 4th. Finally, Barrington Research reaffirmed an "outperform" rating and issued a $125.00 price target on shares of HealthEquity in a report on Friday, August 29th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $119.77.

HealthEquity Stock Performance

Shares of NASDAQ HQY traded down $1.85 during mid-day trading on Friday, hitting $93.74. The company had a trading volume of 1,600,983 shares, compared to its average volume of 1,228,123. HealthEquity, Inc. has a 12 month low of $74.07 and a 12 month high of $116.65. The company has a debt-to-equity ratio of 0.47, a current ratio of 4.23 and a quick ratio of 4.23. The firm's 50 day simple moving average is $92.85 and its two-hundred day simple moving average is $94.06. The stock has a market cap of $8.08 billion, a price-to-earnings ratio of 56.81, a PEG ratio of 1.37 and a beta of 0.50.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.